Enveric Biosciences, Inc.

Listed Company

ENVBCIK 0000890821NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-8.77M

Total Assets

$5.10M

Equity

$4.18M

Shares Out

1.89M

Op. Cash Flow

$-8.14M

Business

Enveric Biosciences, Inc. is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics to treat depression, anxiety, addiction and other psychiatric disorders. Its main offerings include psychedelic-inspired drug candidates derived from its Psybrary™ discovery platform, with lead programs such as the EVM301 Series (EB-003) and the EVM401 Series, and previously the out-licensed EVM201 Series. Key business activities comprise drug discovery and preclinical development, intellectual property management, licensing and academic and scientific advisory partnerships. The company pursues regulatory filings and clinical development primarily in the U.S. and other jurisdictions and engages in out-licensing and collaborative commercialization arrangements internationally.

Summary from filing dated 2025-03-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
General and administrative	6	6	9	12	20
Research and development	3	3	7	8	5
Depreciation and amortization	200,858	337,489	343,982	327,910	656,643
Total operating expenses	9	10	16	27	65
Loss from operations	−9	−10	−16	−27	−65
Other income	2,567	65,990	—	—	—
Interest (expense) income, net	−106	219	3,708	−5,249	—
Total other income	2,461	66,209	−814,379	7	8
Net loss before income taxes	−9	−10	−17	−20	−56
Income tax expense	—	−8,930	−28,913	1	7
Net loss	−9	−10	−17	−18	−49
Less deemed dividend on inducement of warrants	3	—	19,041	33,014	—
Net loss attributable to shareholders	−12	−10	−17	−19	−49
Foreign currency translation	14,479	−24,768	−33,015	−505,932	150,475
Comprehensive loss	−9	−10	−17	−19	−49
Net loss per share - basic	−36.24	−228.48	−121.29	−13	−103.69
Net loss per share - diluted	−36.24	−228.48	−121.29	−13	—
Weighted average shares outstanding, basic	334,719	41,908	143,938	1	472,343
Weighted average shares outstanding, diluted	334,719	41,908	143,938	1	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	5	2	2	18	17
Prepaid expenses and other current assets	259,216	493,558	1	708,053	380,838
Total current assets	5	3	4	18	18
Property and equipment, net	159,234	305,777	507,377	677,485	294,430
Intangible assets, net	—	42,182	210,932	379,686	—
Total other assets	159,234	347,959	718,309	1	9
Total assets	5	3	4	20	27
Accounts payable	581,020	521,747	1	463,275	683,393
Due to related parties	99,875	232,891	23,608	851,008	—
Accrued expenses and other current liabilities	237,505	735,098	—	—	683,393
Total current liabilities	918,400	1	2	4	3
Commitments and contingencies (Note 9)	—	—	—	—	—
Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively	—	—	—	—	—
Total mezzanine equity	—	—	—	885,028	—
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively	—	—	—	—	—
Common stock, $0.01 par value, 100,000,000 shares authorized, 1,061,533 and 56,501 shares issued and outstanding as of December 31, 2025 and 2024, respectively	10,615	565	1,827	20,782	6,519
Additional paid-in capital	120	108	101	94	83
Accumulated deficit	−115	−106	−96	−79	−61
Accumulated other comprehensive loss	−580,038	−594,517	−569,749	−536,734	−30,802
Total shareholders equity	4	2	2	15	22
Total liabilities, mezzanine equity, and shareholders equity	5	3	4	20	27

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Change in fair value of warrant liability	−858	−24,370	—	—	—
Change in fair value of investment option liability	−1,707	−21,620	—	—	—
Stock-based compensation	827,323	2	2	3	13
Deferred offering costs expensed	—	418,200	—	—	—
Amortization of intangibles	42,182	168,750	168,754	168,750	643,333
Depreciation expense	158,676	168,739	175,228	159,160	13,310
Other	−99,230	—	—	—	—
Prepaid expenses and other current assets	250,938	178,496	−6,857	−374,058	826,837
Accounts payable, accrued expenses and other liabilities	−413,864	−834,630	−103,848	263,686	383,199
Due to related parties	−133,016	232,891	—	—	—
Net cash used in operating activities	−8	−8	−14	−17	−11
Proceeds from sale of Common Stock and warrants, net of offering costs	4	—	—	—	3
Proceeds from Common Stock sold for cash pursuant to the ATM Agreement, net of offering costs	2	—	—	—	—
Proceeds from the exercise and inducement of Series A, B, C, and D warrants, net of offering costs	5	3	—	—	3
Proceeds from Common Stock sold under the Equity Distribution Agreement, net of offering costs	—	2	—	17	22
Proceeds from Common Stock sold under the Purchase Agreement, net of offering costs	—	1	—	—	—
Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options	—	2	—	—	—
Payment for offering costs previously accrued	—	−181,857	—	—	—
Net cash provided by financing activities	11	8	−1	18	25
Effect of foreign exchange rate on changes on cash	−1,499	5,354	−10,022	−81,364	144,942
Net increase (decrease) in cash	2	−46,951	−15	367,885	16
Cash paid for interest	—	—	—	5,249	10,316
Income taxes paid	—	5,000	9,507	—	—
Non-cash issuance of round-up shares	860	—	—	—	39
Non-cash issuance of RSA vested shares	393	—	—	—	—
Offering costs accrued not paid	64,588	—	182,724	—	—
Deferred offering costs not paid	5,000	—	—	—	—
Deemed dividend on inducement of warrants	3	—	—	—	—
Issuance of Placement Agent Warrants as offering costs	364,000	—	—	—	—
Issuance of common shares for offering costs	—	771,293	—	—	—
Deferred offering costs charged to offering costs	—	612,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro